Table 1.
Overexpression of miRNA combat chemoresistance by regulating autophagy.
| miRNA | Effect on autophagy | Cancer type | Resistant to | Targets | Ref |
|---|---|---|---|---|---|
| miR-541 | Inhibition | HCC | Sorafenib | ATG2A, RAB1B | (134) |
| miR-375 | Sorafenib | ATG7 | (121) | ||
| miR-223 | Doxorubicin | FOXO3a | (159) | ||
| miR-26a/b | Doxorubicin | ULK1 | (155) | ||
| miR-375 | Sorafenib | ATG14 | (122) | ||
| miR-125b | Oxaliplatin | EVA1A | (163) | ||
| miR-153-3p | Inhibition | NSCLC | Gefitinib | ATG5 | (119) |
| miR-142-3p | Adriamycin, Cisplatin | HMGB1 | (149) | ||
| miR-1 | Cisplatin | ATG3 | (136) | ||
| miR-129-5p | Inhibition | Breast cancer | Taxol | HMGB1 | (150) |
| miR-451a | Tamoxifen | (164) | |||
| miR-214 | Tamoxifen, Fulvestrant | UCP2 | (165) | ||
| miR-27a | Paclitaxel, Doxorubicin | (166) | |||
| miR-489 | Doxorubicin | ULK1 | (157) | ||
| miR-24-3p | Inhibition | SCLC | Etoposide, Cisplatin | ATG4A | (135) |
| miR-30a-5p | Beclin-1 | (131) | |||
| miR-495-3p | Inhibition | Gastric cancer | Multidrug | GRP78 | (167) |
| miR-23b-3p | Multidrug | ATG12 and HMGB2 | (83) | ||
| miR−30 | Multidrug | Beclin-1 | (129) | ||
| miR-874 | Multidrug | ATG16L1 | (138) | ||
| miR-181a | Cisplatin | ATG5 | (116) | ||
| miR-148a-3p | Cisplatin | AKAP1 and RAB12 | (154) | ||
| miR-29c | Inhibition | Pancreatic cancer | Gemcitabine | USP22 | (168) |
| miR-137 | Doxorubicin | ATG5 | (115) | ||
| miR-101 | Inhibition | Osteosarcoma | Doxorubicin | (169) | |
| miR-22 | Cisplatin, Doxorubicin | HMGB1, MTDH | (146, 170, 171) | ||
| miR-199a-5p | Cisplatin | Beclin-1 | (127) | ||
| miR-30a | Doxorubicin | Beclin-1 | (130) | ||
| miR-140-5p | Multidrug | HMGN5 | (152) | ||
| miR-17 | Inhibition | Lung cancer | Paclitaxel | Beclin-1 | (125) |
| miR-106a | Saracatinib, Dasatinib | ULK1 | (156) | ||
| miR-17-5p | Paclitaxel | Beclin-1 | (126) | ||
| miR-200b | Docetaxel | ATG12 | (137) | ||
| miR-26a | Inhibition | Melanoma | Dabrafenib | HMGB1 | (151) |
| miR-216b | Vemurafenib | Beclin-1, UVRAG, ATG5 | (117) | ||
| miR-409-3p | Inhibition | Colon cancer | Oxaliplatin | Beclin-1 | (124) |
| miR-22 | Inhibition | Colorectal cancer | 5-FU | BTG1 | (172) |
| miR-218 | Multidrug | YEATS4 | (173) | ||
| miR-34a | Oxaliplatin | Smad4 | (174) | ||
| miR-199a/b-5p | Inhibition | Chronic myeloid leukemia | Imatinib | WNT2 | (162) |
| miR- 30A | Beclin-1, ATG5 | (118, 128) | |||
| miR-153-3p | Bcl-2 | (120) | |||
| miR-17 | Inhibition | Glioblastoma | Temozolomide | ATG7 | (175) |
| miR-93 | (176) | ||||
| miR-218 | Inhibition | Endometrial carcinoma | Paclitaxel | HMGB1 | (148) |
| miR-30a | Inhibition | Renal cell carcinoma | Sorafenib | Beclin-1 | (177) |
| miR-30a | Inhibition | Various types of cancer | cis-DDP, Taxol | Beclin-1 | (132) |
| miR-34a | Inhibition | Prostate cancer | Topotecan, Doxorubicin | ATG4B | (139) |
| miR-29c-3p | Inhibition | Ovarian cancer | Cisplatin | FOXP1/ATG14 | (140) |
| miR-199a-5p | Inhibition | Acute myeloid leukemia | Adriamycin | DRAM1 | (178) |
| miR-34A | Inhibition | Retinoblastoma | Vincristine, Etoposide, Carboplatin | HMGB1 | (147) |
| miR-15a/16 | promotion | Cervical carcinoma | Camptothecin | Rictor | (179) |
| miR-181 | promotion | NSCLC | Cisplatin | PTEN/PI3K/AKT | (180) |
| miR-193b | promotion | Oesophageal cancer | 5-FU | Stathmin 1 | (181) |
| miR-519a | promotion | Glioblastoma | Temozolomide | STAT3/Bcl2 | (182) |